market down but optr is up why do you know some one is acquiring slowly optr and a buyout is on the process. no shit why big guys dont let you the deal small guys comes in late so be smart and buy and hold see whats is cooking behind the screen.
Jumping right in... Analysts at ThinkEquity lifted their price target on CBST by 50% to $30, according to Briefing.com. The upbeat note comes on the heels of Cubist's recently inked deal with Optimer Pharmaceuticals (OPTR - 13.07) to co-promote and market the latter company's anti-diarrhea antibiotic, which is currently under review by the Food & Drug Administration (FDA). Under the terms of the exclusive, two-year deal, CBST will receive quarterly service fees of $3.75 million.